In a related story about the Broad Institute, this was released today: potential news and warnings of tumors that could become resistant to a common cancer drug when used upon a recurrence of a tumor. There's a lot going on with genomic research at the center and this is just one example. BD
"Automated machines at three Genome Sequencing Centers, including the Broad Institute center led by Eric S. Lander, Broad Institute director, were set to work reading the DNA messages in the cancer cells' nuclei. Of the roughly 20,000 protein-coding genes in the tumor cells, 601 genes were selected by the GBM disease working group for detailed sequencing -- determining the order of chemical "letters" in the DNA -- and comparison. A second installment of genes is already being sequenced, and Chin and her group are working on additional gene lists for mutational analyses.
When such patients were treated with Temodar and subsequently had a recurrence of the tumor, it was very likely to become resistant to treatment because of "hypermutation" -- an increased rate of gene changes that led to the tumor's ability to evade the drugs.
"This could have immediate clinical applications," said Chin."
Eli and Edythe Broad are donating $400 million to the Broad Institute, a biomedical joint venture of Harvard University and the Massachusetts Institute of Technology. The Broads, who live in Los Angeles, originally put $200 million toward the creation of the institute in 2004. The institute was originally intended to serve as a 10-year experimental institute, but with the newest donation, will be converted into a permanent venture.